Comparative Pharmacology
Head-to-head clinical analysis: NORPACE versus QUINACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE versus QUINACT.
NORPACE vs QUINACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)